Reply to Li et al
- PMID: 37855723
- PMCID: PMC10765385
- DOI: 10.1164/rccm.202310-1721LE
Reply to Li et al
Comment on
-
A Daunting and Challenging Task to Prove the Effectiveness of Reducing Acute Exacerbation in COPD Patients with Type 2 Diabetes by GLP-1 Receptor Agonists.Am J Respir Crit Care Med. 2023 Dec 15;208(12):1345-1346. doi: 10.1164/rccm.202309-1671LE. Am J Respir Crit Care Med. 2023. PMID: 37855726 Free PMC article. No abstract available.
References
-
- Knop FK, Aroda VR, do Vale RD, Holst-Hansen T, Laursen PN, Rosenstock J, et al. OASIS 1 Investigators Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet . 2023;402:705–719. - PubMed
-
- Lederer DJ, Bell SC, Branson RD, Chalmers JD, Marshall R, Maslove DM, et al. Control of confounding and reporting of results in causal inference studies. Ann Am Thorac Soc . 2019;16:22–28. - PubMed
Publication types
Grants and funding
- K23HL161332/NH/NIH HHS/United States
- U01 HG008685/NH/NIH HHS/United States
- U01 AI155299/AI/NIAID NIH HHS/United States
- U01 AI1155299/NH/NIH HHS/United States
- R01 HL117945/HL/NHLBI NIH HHS/United States
- U19 AI095219/AI/NIAID NIH HHS/United States
- P30 AR070253/AR/NIAMS NIH HHS/United States
- K23 HL161332/HL/NHLBI NIH HHS/United States
- U19AI095219/NH/NIH HHS/United States
- U01HG008685/NH/NIH HHS/United States
- R01HL136209/NH/NIH HHS/United States
- R01AI136041/NH/NIH HHS/United States
- R01 HL136209/HL/NHLBI NIH HHS/United States
- R01 AI078908/AI/NIAID NIH HHS/United States
- R01AI078908/NH/NIH HHS/United States
- R01HL117945/NH/NIH HHS/United States
- R37AI052353/NH/NIH HHS/United States
- R37 AI052353/AI/NIAID NIH HHS/United States
- U01 HG008685/HG/NHGRI NIH HHS/United States
- R01 AI136041/AI/NIAID NIH HHS/United States
- P30 AR070253/NH/NIH HHS/United States
LinkOut - more resources
Full Text Sources
